Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 7
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study.
Montaudié H, Viotti J, Combemale P, Dutriaux C, Dupin N, Robert C, Mortier L, Kaphan R, Duval-Modeste AB, Dalle S, De Quatrebarbes J, Stefan A, Brunet-Possenti F, Kogay M, Picard-Gauci A, Poissonnet G, Peyrade F. Montaudié H, et al. Among authors: picard gauci a. Oncotarget. 2020 Jan 28;11(4):378-385. doi: 10.18632/oncotarget.27434. eCollection 2020 Jan 28. Oncotarget. 2020. PMID: 32064041 Free PMC article.
ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity.
Cheli Y, Tulic MK, El Hachem N, Nottet N, Jacquel A, Gesson M, Strub T, Bille K, Picard-Gauci A, Montaudié H, Beranger GE, Passeron T, Close P, Bertolotto C, Ballotti R. Cheli Y, et al. Among authors: picard gauci a. Mol Cancer. 2021 Jan 7;20(1):12. doi: 10.1186/s12943-020-01306-2. Mol Cancer. 2021. PMID: 33413419 Free PMC article.
Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients.
Gérard A, Doyen J, Cremoni M, Bailly L, Zorzi K, Ruetsch-Chelli C, Brglez V, Picard-Gauci A, Troin L, Esnault VLM, Passeron T, Montaudié H, Seitz-Polski B. Gérard A, et al. Among authors: picard gauci a. J Immunother Cancer. 2021 Jun;9(6):e002512. doi: 10.1136/jitc-2021-002512. J Immunother Cancer. 2021. PMID: 34088741 Free PMC article.
Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma.
Ilié M, Lantéri E, Chamorey E, Thamphya B, Hamila M, Montaudié H, Picard-Gauci A, Gardrat S, Passeron T, Lassalle S, Long-Mira E, Cherfils-Vicini J, Gilson E, Hofman V, Hofman P. Ilié M, et al. Among authors: picard gauci a. Oncoimmunology. 2021 Mar 19;10(1):1901446. doi: 10.1080/2162402X.2021.1901446. Oncoimmunology. 2021. PMID: 33796413 Free PMC article.
Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity.
Cheli Y, Tulic MK, El Hachem N, Nottet N, Jacquel A, Gesson M, Strub T, Bille K, Picard-Gauci A, Montaudié H, Beranger GE, Passeron T, Close P, Bertolotto C, Ballotti R. Cheli Y, et al. Among authors: picard gauci a. Mol Cancer. 2021 Jan 27;20(1):21. doi: 10.1186/s12943-021-01319-5. Mol Cancer. 2021. PMID: 33504341 Free PMC article. No abstract available.